Method for precise classification and individualized intervention of pigmented skin based on genomic differences
By detecting gene loci related to melanin production and transport, an evaluation model was constructed and personalized skincare products were prepared, solving the problem of the lack of precision in existing skincare products and achieving the effect of personalized skincare.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SHENZHEN HUADA GENE INST
- Filing Date
- 2021-12-15
- Publication Date
- 2026-06-30
AI Technical Summary
Existing skincare products fail to fully consider individual genetic differences during the process of removing blemishes and whitening the skin, resulting in a lack of precision in skincare solutions and an inability to effectively improve pigmentation.
By detecting gene loci related to melanin production and transport, and combining them with skin pigmentation phenotype data, an assessment model for anti-melanin production and transport capacity is constructed. Personalized skincare products containing effective ingredients such as tranexamic acid, niacinamide, and nonapeptide-1 are then developed to precisely intervene in abnormal melanin accumulation in different individuals.
It enables precise skincare solutions based on individual genotypes, effectively improving pigmentation, enhancing the whitening and spot-removing effects and efficiency, and reducing resource waste.
Smart Images
Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention relates to a method for precise subtyping and personalized intervention of pigmented skin based on genomic differences in the field of population-based skincare. Background Technology
[0002] Skin is the largest organ in the human body, maintaining the stability of the internal environment and serving functions such as aesthetics, protection, temperature regulation, and sensory perception. With the improvement of people's living standards, beauty has become a hot pursuit, and skin is a crucial aspect of achieving this. Among current skin problems, pigmentation is a significant and pressing issue that needs to be addressed. Melanin is produced by melanocytes and transported and distributed through dendritic processes connected to epidermal cells, thus forming skin color. Abnormal melanin levels lead to pigmentation.
[0003] Skin pigmentation is caused by a variety of complex factors, including internal and external causes. Common external factors include ultraviolet radiation and chemical drugs, while internal factors are genetic. Genes regulate the production and transport of melanin in the body; excessive melanin synthesis or transport can lead to abnormal melanin accumulation, resulting in age spots.
[0004] Most current skin-lightening and whitening skincare products work by inhibiting melanin production and blocking melanin transport to achieve their effect. However, these products focus more on individual phenotypes, blindly inhibiting melanin production or blocking transport in individuals with existing pigmentation, ignoring the crucial influence of genes on melanin production. With continuous technological advancements, people have gradually realized the impact of genes on individual traits. However, due to differences in genotypes, each person's ability to produce and transport melanin varies. Only by accurately determining each individual's melanin production and transport capabilities can we effectively design skincare products tailored to their individual metabolic needs, achieving precise skincare.
[0005] After recognizing the significant impact of genes on human skin, some gene-based skincare products began to emerge. In 2019, a research team in Ningbo, East China, developed the patented MuseDNA skin gene detection product. This product screened 14 SNP loci from three representative gene groups in Asian populations to systematically assess an individual's skin's anti-aging, anti-inflammatory, anti-photoaging, and anti-pollution capabilities, providing subjects with relatively precise personalized skincare solutions. Jiawenli (Fujian) Cosmetics Co., Ltd. in Fujian invented a detection method for assessing the combination of five major genes in innate skin type (Chinese Patent Application Publication No.: CN 110819723 A). This method detects five SNP loci related to the skin's innate antioxidant capacity, anti-glycation capacity, collagen synthesis capacity, anti-UV capacity, and inflammation control capacity, and develops personalized skincare kits based on the test results. Shaanxi Jiuzhou Medical Laboratory Co., Ltd. invented a susceptibility gene detection panel related to skin aging characteristics and its application (Chinese Patent Application Publication No.: CN110904207 A). This panel assesses an individual's skin condition by detecting 45 SNP loci on 33 skin aging susceptibility genes.
[0006] Most human traits are controlled by multiple genes rather than a single causal gene; therefore, a limited number of genes or SNP loci cannot adequately interpret an individual's skin condition. Existing skin genetic testing products all suffer from a lack of relevant SNP loci.
[0007] Furthermore, current technological solutions still lack gene testing and precise skincare solutions specifically targeting pigmented skin. Existing anti-aging products do not delve into the underlying causes of abnormal melanin accumulation at the gene loci related to pigmented skin. Summary of the Invention
[0008] The technical problem to be solved by this invention is how to accurately improve the condition of pigmented skin, especially the condition of pigment deposition.
[0009] To solve the above-mentioned technical problems, the present invention first provides any of the following applications:
[0010] 1. The application of substances that detect melanin production-related sites and / or melanin transport-related sites and substances that detect skin pigmentation phenotypes in the preparation of products that predict or assist in predicting human anti-melanin production capacity and / or anti-melanin transport capacity;
[0011] 2. Application of substances that detect melanin production-related sites and / or melanin transport-related sites and substances that detect skin pigmentation phenotypes in the preparation of human skin pigmentation products;
[0012] 3. Application of substances that detect melanin production-related sites and / or melanin transport-related sites and substances that detect skin pigmentation phenotypes in the preparation of human skin care products;
[0013] 4. The application of the human anti-melanin production capacity and / or anti-melanin transport capacity assessment model in the preparation of products that predict or assist in predicting human anti-melanin production capacity and / or anti-melanin transport capacity, wherein the human anti-melanin production capacity and / or anti-melanin transport capacity assessment model is constructed based on melanin production-related sites and / or melanin transport-related sites and skin pigment phenotype;
[0014] 5. Application of the human anti-melanin production capacity and / or anti-melanin transport capacity assessment model in the preparation of human skin pigmentation products, wherein the human anti-melanin production capacity and / or anti-melanin transport capacity assessment model is constructed based on melanin production-related sites and / or melanin transport-related sites and skin pigmentation phenotype;
[0015] 6. Application of the human anti-melanin production capacity and / or anti-melanin transport capacity assessment model in the preparation of human skin care products, wherein the human anti-melanin production capacity and / or anti-melanin transport capacity assessment model is constructed based on melanin production-related sites and / or melanin transport-related sites and skin pigment phenotype.
[0016] In the above text, the melanin production-related sites and the melanin transport-related sites can be obtained by genome-wide screening using common statistical models (such as linear regression models, Lasso models, random forest models, etc.). In one embodiment of the present invention, the melanin production-related sites for males are shown in Table 1, the melanin transport-related sites for males are shown in Table 2, the melanin production-related sites for females are shown in Table 1, and the melanin transport-related sites for females are shown in Table 2.
[0017] The assessment model for human anti-melanin production and / or anti-melanin transport capacity can be obtained using common statistical models. The melanin production-related sites and melanin transport-related sites used in this statistical model can be directly selected sites, or a subset of selected sites, and other potentially relevant sites can be added as needed. This statistical model can also be corrected by incorporating factors such as personal skincare habits as independent variables. The skin pigment phenotype data in this statistical model can be obtained using the VISIA image analyzer or AI skin analysis data.
[0018] In the above text, the skin pigmentation phenotypes may be spots, UV spots and / or brown spots, or other phenotypes related to skin pigmentation.
[0019] In the above text, the substance used to detect skin pigmentation phenotypes can be a VISIA image analyzer or other instruments capable of collecting skin pigmentation phenotypes.
[0020] In the above text, the substances used to detect melanin production-related sites and / or melanin transport-related sites may be reagents and / or instruments required for sequencing, such as reagents and / or instruments required for high-throughput sequencing.
[0021] The present invention also provides a product (denoted as Product A), which is composed of substances for detecting melanin production-related sites and / or melanin transport-related sites and substances for detecting skin pigmentation phenotypes, or is composed of substances for detecting melanin production-related sites and / or melanin transport-related sites, substances for detecting skin pigmentation phenotypes, and a human anti-melanin production capacity and / or anti-melanin transport capacity assessment model.
[0022] Product A can be used to prepare products for predicting or assisting in predicting human anti-melanin production capacity and / or anti-melanin transport capacity, or to prepare human skin pigmentation products, or to prepare human skin care products.
[0023] The present invention also provides another product (denoted as product B), which consists of product A and any one of the following X1-X4:
[0024] X1. Skin care products with tranexamic acid as the active ingredient;
[0025] X2. Skincare products with niacinamide as the active ingredient;
[0026] X3. Skin care products with tranexamic acid as the active ingredient and skin care products with nonapeptide-1 as the active ingredient;
[0027] X4. Skincare products with niacinamide as the active ingredient and skincare products with nonapeptide-1 as the active ingredient.
[0028] The content of the active ingredients in the skin care products with tranexamic acid, niacinamide, and nonapeptide-1 as the active ingredient can be increased or decreased according to the actual situation. Other ingredients in each product can also be increased or decreased according to the situation.
[0029] The skincare product containing tranexamic acid as an active ingredient may be a 5% tranexamic acid serum. The skincare product containing niacinamide as an active ingredient may be a 10% niacinamide serum. The skincare product containing nonapeptide-1 as an active ingredient may be a 2% nonapeptide-1 serum.
[0030] Product B can be used for personalized, precise skincare or to improve pigmented skin conditions, especially pigmentation.
[0031] This invention, based on whole-genome sequencing, performs genotyping according to abnormalities in melanin production and transport in the skin. It assesses the skin's ability to resist melanin production and transport by examining the mechanisms of pigmented skin, essentially dividing the population into four types. For each type, a corresponding solution is generated, allowing for the selection of different skincare ingredients tailored to individual skin types. This personalized intervention effectively intervenes in abnormal melanin accumulation, avoiding indiscriminate skincare, saving time and resources in product development, and improving the effectiveness and efficiency of skin whitening and spot removal, truly achieving precision skincare. This invention utilizes genotyping for precision skincare, effectively identifying the skin's genetic strengths and weaknesses, mitigating negative genetic influences on the skin, and reducing or even eliminating potential skin problems. Attached Figure Description
[0032] Figure 1 Design a flowchart for precise skincare.
[0033] Figure 2 A flowchart for constructing a pigment typing model.
[0034] Figure 3 To determine the main component allocation of the intervention product based on the genotyping results, in this invention, niacinamide is a 10% niacinamide essence, tranexamic acid is a 5% tranexamic acid essence, and nonapeptide is a 2% nonapeptide-1 essence.
[0035] Figure 4 Here is the ingredient list for each intervention product.
[0036] Figure 5 The results of skin pigmentation classification for volunteers. (A) Volunteer A, (B) Volunteer B, (C) Volunteer C, (D) Volunteer D.
[0037] Figure 6 Comparison chart of the effects of product intervention on volunteers before and after 1 month (VISIA results). (A) Volunteer A, (B) Volunteer B, (C) Volunteer C, (D) Volunteer D, (E) Volunteer E. Detailed Implementation
[0038] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.
[0039] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials, reagents, instruments, etc., used in the following examples are commercially available.
[0040] Example 1: Construction of a skin melanin assessment model
[0041] This invention provides a skin melanin assessment model (i.e., an anti-melanin production capacity assessment model and an anti-melanin transport capacity assessment model) by combining whole-genome DNA data, VISIA data, and questionnaire data to conduct cross-omics analysis on subjects (see details in the documentation). Figure 1 ).
[0042] The study included over 1000 participants (1068 individuals), with inclusion criteria being healthy individuals possessing whole-genome data and VISIA test data. Among them, 486 were male and 582 were female, with an age range of 20-67 years.
[0043] 1) Data Acquisition
[0044] Whole genome data: Blood or saliva samples were obtained from the subjects for high-throughput sequencing of whole genome DNA. After the data was processed, the original fastq file was converted into g.vcf file format. Genotype deletions were filled using the Beagle tool, and the target mutation SNP site information was extracted from the melanin-related site knowledge base using the Plink software based on the reference genome hg38.
[0045] VISIA data: obtained using the VISIA image analyzer from Canfield. The VISIA image analyzer irradiated the subject's frontal and left facial skin with white light, UV light, and cross-polarized light, detecting and recording eight dimensions of skin features, including spots, wrinkles, texture, pores, UV spots, brown spots, red areas, and porphyrins. The VISIA image analyzer analyzed the image results for each skin feature and output three results: feature count, score, and percentile. The score for each dimension combines information such as the feature value and the area detected. A higher score indicates a more severe skin problem in that dimension.
[0046] Questionnaire data: The survey recorded the subjects' age, skin type (dry or oily), skin sensitivity, sun protection practices, and cosmetic usage.
[0047] Sun protection habits were assessed through a questionnaire. The questionnaire included the question, "Do you have a habit of using sunscreen? (including applying sunscreen, wearing a hat, etc.)" and provided four single-choice options: "Yes, rain or shine."; "I always use sunscreen when exposed to the sun, but not in other situations"; "I rarely use sunscreen, or I don't use it regularly, even when exposed to sunlight"; and "I never use sunscreen." Participants who chose "Yes, rain or shine" were assessed as having regular sun protection habits, while the other options were considered to have irregular sun protection habits.
[0048] Melanin-related loci knowledge base: This database collects and integrates melanin-related loci through literature review. Mutation sites are divided into melanin production-related loci and melanin transport-related loci based on the pathways involved in the genes in which the mutations occur.
[0049] 2) Model Building
[0050] Using melanin production-related sites and melanin transport-related sites from the melanin knowledge base in the whole genome data, and combining pigmentation-related phenotypes (freckles, UV spots, and brown spots on the front and sides of the face) from the VISIA skin analysis results, the data were divided into male and female data according to gender. Anti-melanin production capacity assessment models and anti-melanin transport capacity assessment models were then constructed for males and females respectively (see modeling process below). Figure 2 ).
[0051] Using linear regression and Lasso models, with pigment-related phenotypic scores as the dependent variable and loci as independent variables (in the Lasso model, loci were assigned values: heterozygotes were assigned 2, and homozygotes of the two types were assigned 1 or 3 (homozygotes of pigment synthesis genes were assigned 3, and homozygotes of pigment non-synthesis genes were assigned 1); loci in other models were added as categorical variables without being assigned values), significant mutation sites were screened twice, and sub-models for each phenotype were established using linear regression. The calculated values from each sub-model were adjusted according to the mechanism involved at each locus (melanin production, melanin transport) and summed to obtain two total scores. These total scores were then converted into two percentages. These percentages represent the strength of the subject's anti-melanin production or anti-melanin transport ability in the population. The higher the percentage, the stronger the anti-melanin production / anti-melanin transport ability. The specific steps for constructing the model are as follows:
[0052] Initial screening: A univariate linear regression model was constructed using candidate sites as independent variables and individual VISIA skin pigmentation phenotype scores as dependent variables. A p-value less than 0.1 in the linear regression model was used as the screening criterion to identify significant mutation sites corresponding to the corresponding phenotypes as candidate sites for secondary screening.
[0053] Secondary screening: The significant sites obtained in the initial screening were used as candidate sites as independent variables, and their corresponding phenotypes were used as dependent variables to construct a Lasso model. After five cross-validations, the union of mutation sites with significantly non-zero regression coefficients in the five Lasso model results was considered as the relevant significant sites for the corresponding phenotypes.
[0054] Three-stage screening: The significant loci selected by the Lasso model were used as candidate loci for the third stage of screening, and a linear regression model was constructed with the corresponding phenotypic scores. Loci with p-values less than or equal to 0.05 in the overall model were selected as significant loci. The locus, the genotype of the locus, and its corresponding regression coefficient were recorded. At the same time, the adjusted R-squared coefficient of determination of the overall model was also recorded.
[0055] The significant sites obtained are shown in Table 1-4 below.
[0056] The corrected coefficients of determination are shown in Table 5 below.
[0057] Table 1. Significant loci associated with melanin production in men:
[0058]
[0059] Table 2. Significant loci associated with melanin transport in men:
[0060]
[0061] Table 3. Significant loci associated with melanin production in women:
[0062]
[0063] Table 4. Significant loci associated with melanin transport in women:
[0064]
[0065] Table 5. Model Correction Determination Coefficients
[0066]
[0067] Constructing a skin pigmentation classification model:
[0068] Genotypes of significant loci after three screenings were used as categorical variables and multiplied by the corresponding corrected coefficients of determination to calculate predicted scores for the corresponding skin pigmentation phenotypes. The total score was obtained by multiplying the six scores for the three phenotypes (freckles, UV spots, and brown spots) on the front and side of the face by the corresponding corrected coefficients of determination. The formula for calculating the total score is as follows:
[0069] ,
[0070] in, These are the correction determination coefficients for each sub-model.
[0071] After Z-score normalization correction of the total score, the difference between the cumulative distribution function of 1 and the total score is calculated to obtain the score in the range of 0 to 1, and finally output as a percentage.
[0072] The percentages obtained from assessments of melanin production-related sites indicate the strength of an individual's anti-melanin production capacity in the population, while the percentages obtained from assessments of melanin transport-related sites indicate the strength of an individual's anti-melanin transport capacity in the population. Higher percentages indicate stronger anti-melanin production / anti-melanin transport capacity. The threshold value for distinguishing between strong and weak anti-melanin production capacity is 0.5, and the threshold value for distinguishing between strong and weak anti-melanin transport capacity is 0.4.
[0073] 3) Intervene in determining product ingredients
[0074] In recent years, with the deepening of research, the mechanisms of action of skin-lightening ingredients have gradually become clear. Some skin-lightening ingredients mainly act on inhibiting melanin synthesis, such as tranexamic acid and arbutin. Other ingredients mainly inhibit the transport of melanosomes, such as niacinamide, which is currently a widely used skin-lightening ingredient. This invention selects two main ingredients: tranexamic acid, which inhibits melanin production, and niacinamide, which inhibits melanin transport.
[0075] 4) Precision skincare intervention products and evaluation reports for pigmented skin
[0076] Combining questionnaire surveys and VISIA skin analysis data, the subjects' skin dryness / oiliness, sensitivity, skin spots, UV-induced pigmentation, and brown spots were assessed and analyzed, and appropriate skincare recommendations were provided. Simultaneously, based on a skin melanin assessment model, the subjects' skin's anti-melanin production and anti-melanin transport capabilities were calculated and evaluated, with percentages reflecting the relative strength of each subject's anti-melanin production and anti-melanin transport capabilities within the population.
[0077] The model can assess the strength of a subject's skin's ability to resist melanin production and transport. Based on the differences in these abilities and sun protection practices among individuals, different products are recommended: those with weaker anti-melanin production abilities are advised to use products with tranexamic acid as the main active ingredient, while those with weaker anti-melanin transport abilities are advised to use products with niacinamide as the main active ingredient (see details for specific product allocation). Figure 3 See product ingredients. Figure 4 ).
[0078] Among them, the 2% nonapeptide-1 essence contains nonapeptide-1, undecylate phenylalanine, acetyl glucosamine and amla, with a mass percentage of 2%, 2%, 1% and 1% respectively, and the remainder is water. It is a product of Norsbel Cosmetics Co., Ltd., with the product number BGI test 20191101.
[0079] The 10% Niacinamide Serum contains niacinamide, glycyrrhizin, 4-butylresorcinol, and acetyl glucosamine, with mass percentages of 10%, 2%, 1%, and 1%, respectively, and the remainder is water. It is a product of Norsbel Cosmetics Co., Ltd., with product number BGI20191102.
[0080] The 5% Tranexamic Acid Serum contains tranexamic acid, acetylglucosamine, hydrolyzed corn protein, and 1-methylhydantoin-2-imide in weight percentages of 5%, 1%, 1%, and 1%, with the remainder being water. It is a product of Norsbel Cosmetics Co., Ltd., with product number BGI20191103.
[0081] The moisturizing essence contains hyaluronic acid and propylene glycol. It is a product of Norsbel Cosmetics Co., Ltd., with product number BGI20191104.
[0082] Analysis results, skincare advice and product recommendations, usage instructions, etc., can be summarized in the Precision Skincare Report and given to the subjects.
[0083] Example 2: Application of the skin melanin assessment model
[0084] Volunteers A, B, C, D, and E underwent concurrent VISIA testing, whole-genome sequencing, and questionnaires. Volunteer A was a 29-year-old female; Volunteer B was a 27-year-old female; Volunteer C was a 30-year-old male; Volunteer D was a 29-year-old female; and Volunteer E was a 34-year-old female.
[0085] The melanin production-related sites obtained from the three screenings of each volunteer in Example 1 were used as independent variables and multiplied by their corresponding corrected coefficients of determination to calculate the predicted score for the corresponding skin pigmentation phenotype. The six scores for the three phenotypes (freckles, UV spots, and brown spots) on the front and side of the face were multiplied by the corresponding corrected coefficients of determination to obtain the total score. The total score was then corrected and transformed to obtain a total score ranging from 0 to 1, and finally output as a percentage.
[0086] The corrected total scores for anti-melanin production and anti-melanin transport capabilities of volunteer AE were obtained to assess skin pigmentation. Based on the model classification results and questionnaire results, the volunteers' pigmented skin types and sun protection status are shown below (Table 1). Corresponding intervention products are also provided. Volunteer E served as the control group in the intervention results analysis.
[0087] Table 1. Volunteer skin pigmentation type, sun protection status, and assigned intervention products.
[0088]
[0089] Note: Skin's ability to resist melanin production and transport (see detailed analysis results) Figure 5 ).
[0090] One month after using the product, the skin of the five volunteers was re-tested using the VISIA instrument. The UV pigmentation scores of volunteers A, B, C, and D all decreased, indicating an improvement in their skin's UV pigmentation condition; the UV pigmentation score of volunteer E increased slightly (see details). Figure 6 This indicates that there was no improvement in their skin's UV-induced pigmentation. Volunteer A's UV-induced pigmentation scores before and after product use were 17.126 and 7.204, respectively; Volunteer B's scores were 22.117 and 17.362; Volunteer C's scores were 19.004 and 15.398; Volunteer D's scores were 31.498 and 27.540; and Volunteer E's scores were 23.148 and 27.769.
[0091] The present invention has been described in detail above. For those skilled in the art, the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. Although specific embodiments have been given, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein. Some of the essential features can be applied within the scope of the following appended claims.
Claims
1. The application of the human anti-melanin production capacity and anti-melanin transport capacity assessment model in the preparation of products that predict or assist in predicting human anti-melanin production capacity and anti-melanin transport capacity, wherein the human anti-melanin production capacity and anti-melanin transport capacity assessment model is constructed based on melanin production-related sites and melanin transport-related sites and skin pigment phenotype; The model construction steps include: Using information on melanin production-related sites and melanin transport-related sites from the melanin knowledge base in the whole genome data, and combining pigment-related phenotypes in skin test results, the data were divided into male and female data according to gender, and anti-melanin production capacity assessment models and anti-melanin transport capacity assessment models were constructed for males and females respectively; the pigment-related phenotypes are spots, ultraviolet spots, and brown spots on the front and side of the face. Initial screening: Using candidate sites as independent variables and individual skin pigmentation phenotype scores as dependent variables, a univariate linear regression model is constructed. Based on the p-values of the linear regression model, significant mutation sites corresponding to the phenotypes are selected as candidate sites for secondary screening. Secondary screening: The significant sites obtained in the initial screening are regarded as candidate sites as independent variables, and their corresponding phenotypes are used as dependent variables to construct a Lasso model. The union of mutation sites with regression coefficients that are significantly non-zero is regarded as the relevant significant sites of the corresponding phenotype. Three-stage screening: The significant loci selected by the Lasso model are regarded as candidate loci for three-stage screening. A linear regression model is constructed with the corresponding phenotypic scores. Loci with p-values less than or equal to 0.05 in the overall model are selected as significant loci. The locus, the genotype of the locus, and its corresponding regression coefficient are recorded. At the same time, the corrected coefficient of determination of the overall model is also recorded. Genotypes of significant loci after three screenings were used as categorical variables and multiplied by the corresponding corrected coefficients of determination. Predicted scores for the corresponding skin pigmentation phenotypes were then calculated. The total score was obtained by multiplying the scores for three phenotypes (freckles, UV spots, and brown spots) on the front and side of the face by their respective corrected coefficients of determination. The formula for calculating the total score is as follows: Where α is the correction determination coefficient of each sub-model.
2. The application of the human anti-melanin production capacity and anti-melanin transport capacity evaluation model described in claim 1 in the preparation of human skin pigmentation products.
3. The application of the human anti-melanin production capacity and anti-melanin transport capacity evaluation model described in claim 1 in the preparation of human skin care products.